Physician

Yuvraj Choudhary, M.D.

According to 2025 Medicare claims, Yuvraj Choudhary, M.D. (NPI: 1396988747) practices hematology/oncology in the Richmond, VA market, with the plurality of this provider's patient population coming from Chesterfield, VA. This provider's primary affiliated billing organization is VIRGINIA CANCER INSTITUTE INCORPORATED (NPI: 1730130980; TIN: 54-1066435) and primary practice location at 23235-4730.

Choudhary's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 845 traditional Medicare patients, billed 152,983 HCPCS/CPT codes, and received $3,691,320 in Medicare payments. The top billing code was 96413 (Administration of chemotherapy into vein, 1 hour or less). Part D data shows 1,384 prescription claims across 222 beneficiaries totaling $5,487,827 in drug costs, led by Revlimid (Lenalidomide). DME data shows 51 claims. Open Payments data shows 53 records totaling $241,989. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has risen steadily, from $83,053 to $3,691,320. Similarly, Part D prescription costs have risen steadily, from $49,920 to $5,487,827. In contrast, DME billing represents a smaller volume and moved up and down with repeated peaks and valleys, starting at $2,338 and ending at $843.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	87	2,102	$83,053
2016	717	133,423	$1,880,394
2017	843	190,151	$2,902,130
2018	894	262,774	$3,559,006
2019	961	289,424	$4,595,120
2020	879	198,560	$3,566,664
2021	914	193,638	$3,845,456
2022	837	192,847	$3,880,659
2023	858	163,293	$3,630,592
2024	845	152,983	$3,691,320

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	29	84	$49,920
2016	98	349	$99,247
2017	148	616	$528,985
2018	150	652	$838,682
2019	174	1,071	$3,014,102
2020	158	1,317	$5,032,073
2021	188	1,357	$5,954,677
2022	206	1,493	$6,243,941
2023	216	1,428	$4,829,293
2024	222	1,384	$5,487,827

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	N/R	N/R
2016	N/R	48	$1,134
2017	N/R	23	$575
2018	N/R	N/R	N/R
2019	N/R	N/R	N/R
2020	N/R	31	$3,635
2021	N/R	N/R	N/R
2022	N/R	32	$1,639
2023	N/R	112	$6,122
2024	N/R	51	$1,388

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
96413	Administration of chemotherapy into vein, 1 hour or less	122	449	$95
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	347	1,351	$93
99213	Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more	441	971	$61
G2211	Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's	277	421	$12
96372	Injection of drug or substance under skin or into muscle	99	264	$10

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Revlimid	Lenalidomide	119	3,227	$2,492,747
Imbruvica	Ibrutinib	60	1,726	$827,784
Lenalidomide	Lenalidomide	24	672	$396,298
Pomalyst	Pomalidomide	17	476	$391,852
Ninlaro	Ixazomib Citrate	21	588	$278,944

Top 5 DME services in 2024

By Total Medicare Payment Amount.

HCPCS Code	HCPCS Description	Supplier Rental Indicator	Total Supplier Beneficiaries	Total Supplier Claims	Total Medicare Payment Amount
J8521	Capecitabine, oral, 500 mg	N	N/R	21	$892
Q0511	Pharmacy supply fee for oral anti-cancer, oral anti-emetic or immunosuppressive drug(s); for the first prescription in a 30-day period	N	N/R	19	$358
Q0512	Pharmacy supply fee for oral anti-cancer, oral anti-emetic or immunosuppressive drug(s); for a subsequent prescription in a 30-day period	N	N/R	11	$138

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	39	$841	PFIZER INC.
Research Payments	Reported research-related payment or transfer-of-value amount.	14	$241,148	ADC Therapeutics America, Inc.
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Yuvraj Choudhary, M.D.?

Tedicare shows public-source Medicare data for Yuvraj Choudhary, M.D. (NPI 1396988747), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Yuvraj Choudhary, M.D. have ACO affiliation data?

No ACO affiliation record is shown in the available Tedicare data for this profile.

What billing organization is linked to Yuvraj Choudhary, M.D.?

Yuvraj Choudhary, M.D. is linked to VIRGINIA CANCER INSTITUTE INCORPORATED (billing NPI 1730130980) in the available physician profile data.

Does Yuvraj Choudhary, M.D. have Open Payments data?

Yuvraj Choudhary, M.D. has 53 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.